推薦產品
化驗
≥98% (HPLC)
形狀
powder
光學活性
[α]/D +75 to +90°, c = 1 in dichloromethane
顏色
white to tan
溶解度
DMSO: ≥19 mg/mL
儲存溫度
2-8°C
SMILES 字串
CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]23C
InChI
1S/C26H32F2O7/c1-13(29)33-12-20(32)26-21(34-22(2,3)35-26)10-15-16-9-18(27)17-8-14(30)6-7-23(17,4)25(16,28)19(31)11-24(15,26)5/h6-8,15-16,18-19,21,31H,9-12H2,1-5H3/t15-,16-,18-,19-,21+,23-,24-,25-,26+/m0/s1
InChI 密鑰
WJOHZNCJWYWUJD-IUGZLZTKSA-N
基因資訊
human ... NR3C1(2908)
尋找類似的產品？ 前往 產品比較指南
生化／生理作用
Flucinonide is a fluorinated glucocorticid that is used as a topical anti-inflammatory agent. Recently, flucinonide and other fluorinated glucocorticolids were identified as smoothend agonists. Flucinonide induces expression of Gli-reporter luciferase in Shh-LIGHT2 cells.
Fluocinonide has been used to study its effect on T-cell proliferation.[1]
Fluocinonide is shown to be effective in the treatment of atopic dermatitis and oral lichen planus (OLP).[2][3]
very potent corticosteroid
訊號詞
Danger
危險聲明
危險分類
Acute Tox. 2 Oral - Repr. 2
儲存類別代碼
6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
從最近期的版本中選擇一個：
Małgorzata Radwan-Oczko
Advances in clinical and experimental medicine : official organ Wroclaw Medical University, 22(6), 893-898 (2014-01-17)
Oral lichen planus is a common, chronic mucosal disease associated with a cell-mediated immunological dysfunction. The clinical manifestation is different when various forms, white and red, are considered. Erosive, atrophic, ulcerative lesions require long-term treatment, because of inflammation and severe
Emily Hix et al.
Dermatology online journal, 19(10), 20029-20029 (2013-10-22)
Adherence in the treatment of chronic inflammatory skin diseases such as atopic dermatitis is poor. Methods to improve adherence have proven difficult. To determine whether a short course of treatment with a high-potency corticosteroid will improve adherence compared to longer
Tinea incognito.
Rhonda Lesniak
Dermatology nursing, 20(5), 403-404 (2008-12-06)
Matthew T Woods et al.
Journal of drugs in dermatology : JDD, 10(2), 171-176 (2011-02-02)
To determine the effect a novel formulation of fluocinonide cream on skin barrier function in subjects with atopic dermatitis. The authors performed an open-label, investigator-blinded, side-by-side, controlled trial examining skin barrier function before and after a two-week course of a
Payman Kosari et al.
Dermatology online journal, 15(3), 15-15 (2009-04-22)
Topical corticosteroids are the primary treatment for psoriasis. A patient with psoriasis being treated with topical fluocinonide for lesions on the extremities developed an erythematous facial eruption consistent with perioral dermatitis. When topical agents are applied, they often end up
Active Filters
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務
